Advertisements

Prednisolona

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Prednisolona

Quick Facts

Property Description
Active ingredient Prednisolone Acetate
Form Ophthalmic Suspension, Ointment, Solution
Pharmacological class Corticosteroid
Common use Controlling inflammation and allergic reactions
Origin Synthetic (Glucocorticoid analogue)

What is Prednisolona? Defining the Active Compound and Class

Prednisolona is a medicinal entity containing the active ingredient Prednisolone Acetate, which is formally classified as a corticosteroid. Specifically, it functions as a potent synthetic glucocorticoid, an analogue chemically synthesized from the naturally occurring adrenal hormone cortisol. This modification, which includes the Acetate functional group, enhances the compound's stability and increases its anti-inflammatory potency compared to related analogues like hydrocortisone. The drug is therefore utilized to leverage powerful regulatory actions on the body's inflammatory and immune pathways, an action clinically recognized for its rapid onset in modulating immune response.

Understanding Prednisolona's Form and Purpose

The general purpose of Prednisolona is to provide rapid and intensive control over destructive inflammation and severe allergic reactions. The drug is primarily manufactured for topical administration, most commonly in sterile dosage form(s) such as an ophthalmic suspension (eye drops), an ointment, or a solution. Topical corticosteroids are frequently indicated for local inflammation; accordingly, the medicine is designed to reduce swelling and redness at the site of application. This targeted approach allows the medicine to concentrate its actions, which involve the immunosuppressive effect and suppression of key cellular responses, directly at the site of inflammation. By modulating the immune response and rapidly decreasing the swelling, redness, and discomfort, Prednisolona’s core function is to achieve a decisive anti-inflammatory effect where localized action is required, due to its potent immunosuppressive properties.

Advertisements

What side effects are possible with Prednisolona?

Possible Side Effects and Safety Information

The official safety profile for Prednisolone Acetate (Prednisolona), a potent synthetic glucocorticoid, is structured by regulatory bodies to outline risks associated with its action on the body’s endocrine and immune systems. The adverse reactions are classified across major system-organ classes, including Endocrine, Metabolic, Musculoskeletal, and Psychiatric systems.

Frequency and System Classification

Adverse effects are categorized by frequency, with reactions such as insomnia, increased appetite, fluid retention, and mild hypertension often classified as Common in regulatory documents. Conversely, effects such as peptic ulceration, posterior subcapsular cataracts, and severe osteoporosis are generally listed as Uncommon or Rare.

Documented Serious Adverse Reactions

Serious reactions officially documented include a heightened risk of developing or exacerbating opportunistic infections due to the drug’s immunosuppressive properties. Other clinically significant reactions include the development of glaucoma (increased intraocular pressure), potential for gastrointestinal hemorrhage, and the risk of adrenocortical insufficiency upon abrupt withdrawal following prolonged therapy.

Exposure and Population-Specific Notes

The most significant risks, such as the development of a Cushingoid state, severe osteoporosis, and ocular damage, are generally associated with prolonged administration. Regulatory documents also include specific safety considerations for patient populations: the risk of growth retardation is noted for the pediatric population, and there is an increased incidence of osteoporosis documented for older adults. Furthermore, the use of Prednisolona is contraindicated in individuals with systemic fungal infections due to the risk of exacerbation.

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory classification for Prednisolona (Prednisolone Acetate ophthalmic suspension) confirms that overdosage will not ordinarily cause acute systemic problems when administered via the eye. This is due to the minimal systemic absorption of the product through the intended topical route. Therefore, the acute systemic risk is considered low.


Despite the low acute risk, specific emergency actions are officially mandated if the product is accidentally ingested (swallowed). In this circumstance, immediate medical attention must be sought, or a Poison Control Center should be contacted. The initial procedural instruction following ingestion is to drink fluids to dilute the product.


Management of a potential systemic overdose is generally limited to symptomatic and supportive treatment, as regulatory documents state no specific antidote is known for prednisolone. It is also important to note that prolonged or excessive topical use, particularly in infants and children, may increase the possibility of chronic systemic effects such as adrenal suppression and Cushing's syndrome. Urgent medical help must also be sought if serious general symptoms occur, such as trouble breathing or passing out.

Advertisements

Therapeutic Uses of Prednisolona

Quick Facts: Therapeutic Domains

  • May help manage certain forms of arthritis and rheumatic disorders.
  • Used to address severe allergic conditions unresponsive to standard approaches.
  • A treatment option for certain respiratory and skin conditions.
  • Can support the management of various autoimmune and inflammatory diseases.

Prednisolona is a medication employed to address a broad range of therapeutic domains where managing inflammation and immune system response is a key objective. It is considered a relevant therapeutic option for certain endocrine, rheumatic, and respiratory disorders, among other uses.

In rheumatology, this medication may help manage acute episodes or exacerbations of conditions such as psoriatic arthritis, rheumatoid arthritis, and systemic lupus erythematosus. It is also used to help provide meaningful comfort from debilitating joint pain associated with these conditions. For certain severe or incapacitating allergic conditions, such as seasonal or perennial allergic rhinitis and bronchial asthma, Prednisolona may be initiated when conventional treatment has not been sufficient.

Additional uses include addressing flare-ups of gastrointestinal diseases, including ulcerative colitis and regional enteritis, to tide the patient over a critical period of the disease. It can also support the management of specific blood disorders and is used for palliative management of certain neoplastic conditions, such as leukemias and lymphomas. The approved indications for this medication are extensive and should be discussed with a qualified healthcare provider for specific guidance.

Advertisements

Eligibility and Restrictions for Use

Who Can and Cannot Use Prednisolona?

Eligibility for Prednisolona is determined by regulatory labeling, focusing on patient characteristics and pre-existing conditions.

Contraindications and Prohibited Use

Prednisolona is contraindicated and must not be used in patients with systemic fungal infections or a known hypersensitivity to the active ingredient or any component of the formulation. Corticosteroid use is also avoided in patients with cerebral malaria.

Restricted and Conditional Use

Population/Condition Regulatory Requirement (Caution/Restriction)
Infectious Status Use requires particular care in non-immune patients to avoid measles or chickenpox; great care is also required with known Strongyloides infestation.
Organ Function Use requires caution in patients with conditions such as Renal Insufficiency, Hypertension, Congestive Heart Failure, and active/latent peptic ulcer.

Age and Maternal Status

Use is not established for certain specific indications in children younger than 2 years old. Older adults require cautious dose selection due to a higher frequency of decreased organ function. In pregnancy (FDA Category C), use is permitted only when the potential benefit outweighs the potential risk to the fetus. Nursing mothers must decide whether to discontinue nursing or discontinue the drug, as it passes into human milk.

Advertisements

What should I know about interactions with other medicines?

The official interaction profile for Prednisolona is defined by effects on systemic exposure and additive pharmacodynamic risks documented in government regulatory sources.

Pharmacokinetic Interactions

Co-administration with CYP 3A4 inducers, such as Rifampin or Phenytoin, may increase the clearance of the corticosteroid, which can affect therapeutic management. Conversely, CYP 3A4 inhibitors, including Ketoconazole and Ritonavir, have the potential to cause increased plasma concentrations of Prednisolona due to reduced hepatic metabolism. Estrogens (including oral contraceptives) may similarly decrease metabolism, potentially increasing the corticosteroid's effect. The agent Aminoglutethimide is documented to potentially lead to the loss of corticosteroid-induced adrenal suppression.

Pharmacodynamic Interactions and Restrictions

Use alongside Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) increases the documented risk of gastrointestinal side effects. Potassium-depleting agents reinforce the risk of hypokalemia, while Antidiabetic Agents may experience a counteracting effect due to Prednisolona's potential to increase blood glucose concentrations. Regarding restrictions, Live or Live Attenuated Vaccines are prohibited (must not be administered) during therapy at immunosuppressive doses. A timing-based rule requires that Anticholinesterase Agents be withdrawn at least 24 hours before initiating Prednisolona in patients with Myasthenia Gravis. The risk of tendon rupture with co-administered Fluoroquinolones is specifically noted as increased in the elderly population.

Advertisements

Mechanism of Action

️ How Prednisolone Works: The Core Mechanisms

Genomic Suppression of Inflammatory Signals

Prednisolone, acting as an agonist, binds to the intracellular Glucocorticoid Receptor ( GR), and the resulting complex moves into the nucleus to act on gene expression. This action involves two coordinated steps: transrepression, which functionally silences pro-inflammatory transcription factors like NF-kappa B, and transactivation, which activates genes that synthesize anti-inflammatory proteins. This cellular mechanism modulates immune and inflammatory pathway activity.


Upstream Modulation of the Arachidonic Acid Cascade

The GR mechanism promotes the production of the protein Annexin-1, which indirectly inhibits the enzyme Phospholipase A2 ( PLA2). By blocking PLA2, the drug limits the initial step of the Arachidonic Acid Cascade, reducing the synthesis of eicosanoids such as prostaglandins and leukotrienes. This mechanistic block affects physiological changes such as increased vascular permeability and vasodilation.

Advertisements

Dosage and Administration Information

Prednisolona is used through two officially approved administration routes defined by its intended therapeutic scope: Oral for systemic action and Topical Ophthalmic for localized application to the eye. The oral route utilizes tablets or solutions, while the ophthalmic route uses sterile suspensions or ointments.

The systemic dosing schedule is structured in phases. The initial daily dose for adults typically ranges from 5 mg to 60 mg, adjusted according to the specific condition. Following this initial phase, the dose must be gradually reduced (tapered) to determine the lowest dosage that sustains a clinical response. This tapering is a mandatory procedural constraint when discontinuing long-term or high-dose therapy. Oral forms should be consumed with food or milk to adhere to official intake instructions.

Frequency patterns include once daily administration—often preferred in the morning—or in divided doses. For topical use, the ophthalmic suspension must be shaken well before instillation of one to two drops. The frequency is usually two to four times daily but can be increased to up to hourly in the acute phases of severe inflammation. Population-specific rules dictate that pediatric dosing for systemic use is calculated based on body weight or body surface area, rather than fixed adult regimens.

Advertisements

Recent Clinical Evidence

Research evidence / Overview of studies for Prednisolona

Evidence for use in Inflammatory Conditions (e.g., Rheumatoid Arthritis, Asthma)

Prednisolona was studied for use in conditions characterized by fluctuating or episodic manifestations linked to inflammation, such as certain types of arthritis or respiratory issues. Research in these areas examined outcomes related to physical discomfort and outcomes reflecting daily functioning or activity level. For many of these inflammatory conditions involving periods of heightened symptoms, the evidence describes patterns observed regarding inflammation. Studies reported patterns of short-term changes in symptoms associated with its use. Despite these findings, comparative evidence is lacking in some areas, and the data for certain groups remain insufficient. The results apply only to the populations studied, and long-term effects are not fully established.


Evidence for use in Allergic Reactions and Conditions

This section outlines the studies that have examined how Prednisolona was studied for use in acute and chronic allergic responses, such as severe allergies or certain skin conditions. Research examined outcomes linked to inflammatory or irritative states. Studies examining temporary physiological imbalance used research exploring short-term symptom changes to assess how Prednisolona was observed in these settings. Findings from various research scenarios describe patterns related to outcomes during periods of heightened symptom activity. The certainty remains low for some of the less common allergic conditions, and evidence quality varies across studies.


Long-term Studies and Follow-up

Studies evaluating the long-term use of Prednisolona are crucial but often face challenges, as follow-up durations were limited in many initial trials. The available data describes how symptoms evolved over time. The available evidence for the long-term status of observed patterns is still emerging, and the impact on systemic or functional imbalance over very extended periods is not fully established. These findings describe group patterns, not personal outcomes, and highlight what is known and what is still uncertain.


Evidence in Special Populations

Research specifically addressing special populations is limited, meaning that data for certain groups remain insufficient. Prednisolona was evaluated in studies involving children, particularly for respiratory conditions characterized by fluctuating or episodic manifestations, but sample sizes were modest. For older adults and individuals with complex co-existing health issues, subgroup findings are uncertain, and there is limited information for long-term outcomes specific to these unique populations.

Key Studies & References Study of Short-term Symptom Patterns in Conditions with Episodic Manifestations: A Randomized Controlled Trial

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Prednisolona (FAQ)

Q: How quickly do the effects of Prednisolona start to become noticeable?

A: Official information indicates that after taking the oral form, the onset of action may begin within a few hours. However, the complete anti-inflammatory and immune-modulating effects may take a few days to fully develop. The speed with which noticeable effects appear is described as varying depending on the specific condition being addressed.

Q: Can Prednisolona cause weight gain, and if so, why?

A: Yes, official documents describe that weight gain is a possible effect of systemic use. This is often associated with two factors: an increase in appetite and the body retaining extra water, which is medically known as fluid retention.

Q: Are there any long-term effects described in official drug information for Prednisolona?

A: Official safety documents indicate that prolonged systemic use of corticosteroids is associated with several potential long-term effects. These may include a decrease in bone density, which can lead to thinner bones (osteoporosis), high blood pressure, and specific changes to the endocrine system (adrenal suppression).

Q: Why do some people experience trouble sleeping while taking Prednisolona?

A: Trouble sleeping, or insomnia, is listed as a common side effect of systemic corticosteroid medicines. Official guidance sometimes suggests a morning administration time, which may be one approach considered for managing this effect.

Q: What is the information available on Prednisolona use during pregnancy?

A: Prednisolona is classified as Pregnancy Category C by the FDA. This means that while animal studies have suggested a potential risk to the fetus, there are no adequate studies in pregnant women. Official advice permits its use only when the potential benefit for the person warrants the potential risk to the developing fetus.

Q: Is it possible for Prednisolona to cause stomach irritation?

A: Yes, official safety information notes the potential for gastrointestinal side effects. These include stomach irritation, indigestion (dyspepsia), and the risk of peptic ulceration, particularly when the medicine is used in combination with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs).

Q: How long can a person typically expect to be on Prednisolona?

A: The expected duration of treatment with Prednisolona is highly variable and depends entirely on the specific health condition being managed. It may be prescribed for very short courses, such as for an acute allergic reaction, or for longer, extended periods for chronic, ongoing inflammatory conditions.

Q: What is the general duration of action for a single dose of Prednisolona?

A: The general duration of action for a single systemic dose of Prednisolona is described in official sources as lasting between approximately 12 to 36 hours. This timeframe represents how long the medicine remains active in the body to produce its effects.

Q: Does Prednisolona cause insomnia?

A: Yes, official safety profiles list insomnia (trouble sleeping) as a common side effect for individuals taking systemic Prednisolona. This is a recognized effect of the corticosteroid class of medicines.

Q: Does Prednisolona come in a liquid form for those who have trouble swallowing?

A: Prednisolona is manufactured in various liquid formulations, including solutions and suspensions. While these forms are necessary for accurately dosing children, they may also serve as an alternative option for individuals with difficulty swallowing tablets.

Q: What is the difference between Prednisolona and Prednisone?

A: The official difference is that Prednisone is a pro-drug, meaning it is biologically inactive when taken. It must be processed by the liver and chemically converted into the active medicine, which is Prednisolone, before it can work in the body.

Q: Is there a risk of becoming dependent on Prednisolona?

A: The need for gradual dose reduction (tapering) after long-term use is a mandatory procedure documented to support the body’s readaptation and manage potential withdrawal symptoms. This process is important to prevent adrenal crisis or disease flares.

Q: Do official sources list specific foods or drinks to avoid while taking Prednisolona?

A: Official sources specifically warn against consuming real liquorice. This substance is documented to increase the concentration of Prednisolona in the body and can potentially heighten the risk of developing low potassium levels.

Q: Is it normal to feel more anxious or irritable while on Prednisolona?

A: Yes, official safety documents note that psychiatric reactions, including an irritable mood, are documented with systemic corticosteroid use. These psychological effects can potentially start within a few days or weeks after beginning treatment.

Q: Why is Prednisolona sometimes prescribed for conditions outside of arthritis or asthma?

A: The official uses of Prednisolona are extensive because of its broad anti-inflammatory and immunosuppressive actions. The medicine is also officially used to treat various blood disorders, certain skin conditions, specific infections, and to help prevent the body from rejecting a transplanted organ.

Q: Why are people often told to take Prednisolona in the morning?

A: Official information describes that taking the medicine as a single dose in the morning is the preferred timing. This schedule is intended to minimize the medicine's suppressive effect on the body's natural production of cortisol by the adrenal glands, which is highest in the early morning.

Q: Are there any official warnings about combining Prednisolona with diuretics (water pills)?

A: Official documents caution that combining Prednisolona with medicines categorized as Potassium-depleting agents increases the risk of low potassium levels (hypokalemia). Certain diuretics are classified as potassium-depleting and should be managed with caution.

Q: Are changes in mood a potential effect of Prednisolona, according to regulatory documents?

A: Yes, regulatory safety profiles list various psychological effects and affective disorders as potential effects of systemic use. These documented reactions include changes such as mood swings (labile mood), feeling euphoric or agitated, and feelings of depression or anxiety.

Q: Does Prednisolona affect fertility?

A: Official safety information indicates there is no clear evidence available to suggest that taking systemic Prednisolona reduces fertility in either men or women.

Q: What is the difference between systemic and topical Prednisolona?

A: Systemic Prednisolona, such as the oral form, is absorbed into the bloodstream and affects the entire body to provide widespread anti-inflammatory effects. Topical forms, like ophthalmic suspensions, are applied to a specific area (e.g., the eye) to deliver a concentrated, localized effect with less overall exposure to the body.

Q: What research themes are associated with Prednisolona in clinical studies?

A: Clinical studies often focus on themes related to optimizing treatment and safety. Key research themes include finding the best way to balance the medicine's therapeutic benefits against its side effects, exploring optimal dosing schedules (such as morning dosing), and developing strategies to reduce known long-term risks.

Q: Is fatigue a common experience when taking Prednisolona?

A: While not generally listed as a common effect during ongoing treatment, official documents indicate that severe fatigue or extreme tiredness is a documented possible symptom. This effect is often noted when the medicine is discontinued too quickly.

Q: Can Prednisolona be taken with supplements or herbal products?

A: Official resources note that there is very little information available regarding the safety of combining herbal products or dietary supplements with this medicine. It is not possible to provide blanket assurances regarding interactions with these products.

Q: Is Prednisolona commonly used for skin conditions?

A: Yes, official sources confirm that systemic Prednisolona is used to treat a wide variety of conditions. This includes various skin diseases that involve inflammation, such as severe cases of eczema, dermatitis, or other inflammatory dermatoses.

Q: Are there restrictions on Prednisolona use for people with high blood pressure?

A: Official documentation states that using Prednisolona in individuals with high blood pressure (Hypertension) requires caution and close monitoring. This is because the medicine has the potential to elevate blood pressure, but it is not listed as an absolute prohibition for use.

Q: Can Prednisolona interact with birth control pills?

A: Yes, official documents indicate that Estrogens, which are found in oral contraceptive pills, may interfere with the body’s breakdown of Prednisolona. This interaction can potentially slow the drug’s clearance, leading to an increase in the corticosteroid’s concentration and effects in the body.

Q: How does Prednisolona affect the body's inflammatory response?

A: Prednisolona acts on inflammatory pathways to suppress the body’s response. At a high level, it works to suppress multiple inflammatory genes and transcription factors that are activated during the inflammatory process. It also promotes the synthesis of proteins that have anti-inflammatory effects.

Q: What are the official contraindications listed for Prednisolona?

A: Official documents list specific conditions where use is prohibited, which are referred to as contraindications. These include known hypersensitivity or allergy to the medicine's components and the presence of widespread systemic fungal infections.

Q: How soon after starting Prednisolona should a person expect improvement for inflammation?

A: If the dose prescribed is effective for the condition, a person may start to notice an effect at reducing inflammation within a few hours to a few days after taking the first dose. Symptom improvement is typically a gradual process.

Q: What is the typical age range for people who are prescribed Prednisolona?

A: Official dosing and safety information is provided for a broad range of ages, including adults, infants, and children. Dosing for children is calculated based on body weight or surface area, and older adults require careful dose selection due to common age-related organ function changes.

Q: What are some common misunderstandings about how Prednisolona is used?

A: Common misunderstandings often documented in medical literature revolve around important safety procedures. These include errors related to the mandatory tapering of the dose, selecting the appropriate drug choice for the condition, and the need for appropriate prophylaxis (preventive treatments) to mitigate known risks.

Q: What information is provided about the risk of infection while taking Prednisolona?

A: Regulatory documents note a heightened risk of developing or exacerbating infections, including serious and opportunistic infections. This is a direct consequence of the drug’s fundamental property of suppressing the immune system.

Advertisements

How should Prednisolona be stored and disposed of?

Storage and Disposal Requirements for Prednisolone

Storage instructions for Prednisolone must strictly follow the official product label, as requirements vary by formulation.


Storage Conditions

Most formulations require storage at Controlled Room Temperature (20 C to 25 C), but some specific liquid forms must be refrigerated (2 C to 8 C) before opening. All products must be protected from light and freezing, as freezing may alter the medicine. Containers must be kept tightly closed and out of the sight and reach of children.

Disposal Instructions

Unused or expired Prednisolone must be disposed of in accordance with local requirements. The medicine should not be thrown into household waste or wastewater; it must be returned to a pharmacy or designated collection program for proper environmental handling.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Prednisolona found in:

A-Z Index: